BCMA is preferentially expressed on plasma cells and other mature B cells in blood 5. These cells originate ... chimeric antigen receptor (CAR) T cells have the longest history of clinical ...

A clinical team has spearheaded the use of CAR-T cell therapy for blood cancers. The researchers recently treated the first ...

Johnson & Johnson and Legend Biotech’s BCMA-targeted CAR ... as well as a risk for secondary blood cancers in line with an FDA review of the safety of the entire CAR-T class earlier this year.

2seventy bio worked with BMS on the development of BCMA-directed CAR-T therapy Abecma (idecabtagene vicleucel), used to treat blood cancer multiple myeloma, which brought in $406 million in sales ...

This CAR helps the T cells recognize and destroy cells expressing BCMA, which is primarily found in malignant multiple myeloma B-lineage cells, late-stage B cells, and plasma cells. The CARVYKTI ...

Schematic illustration explaining the working principle of BCMA-CD19 bispecific CAR T cells used in current study. CD19 is the pan B cell marker but not expressed in long-lived plasma cells and ...